Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Vipoma 2Somatostatinoma 2Rectal Neoplasms 2Insulinoma 2Glucagonoma 2Gastrinoma 2Colorectal Neoplasms 2Carcinoma, Islet Cell 2Thymoma 1Neuroendocrine Tumors 1Neoplasms 1Meningioma 1Drug-Related Side Effects and Adverse Reactions 1Diarrhea 1Colonic Neoplasms 1Breast Neoplasms 1Anus Neoplasms 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 39Docetaxel 30Tamoxifen 29Paclitaxel 27Doxorubicin 26Trastuzumab 20Radiotherapy 18Epirubicin 16Letrozole 13exemestane 11Fluorouracil 11Anastrozole 11Capecitabine 10Bevacizumab 10Immunohistochemistry 9Filgrastim 9Fulvestrant 8Methotrexate 7Gene Expression Profiling 7palbociclib 6Zoledronic Acid 6Microarray Analysis 6Lapatinib 6Goserelin 6Chemotherapy, Adjuvant 6Amplified Fragment Length Polymorphism Analysis 6Vinorelbine 5Triptorelin Pamoate 5Carboplatin 5Absorptiometry, Photon 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Breast Neoplasms × Octreotide × Clear all
NCT00002864 2020-04-01

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

Canadian Cancer Trials Group

Phase 3 Completed
667 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡